FEIBA prophylaxis in a patient with haemophilia and inhibitors

Hook, Susan

doi:10.17225/jhp.00031

Abstract

A case study is presented illustrating the everyday challenges faced by patients with haemophilia and inhibitors and how treatment with bypassing agents or just FEIBA prophylaxis can help to control bleeding and improve functional ability.

References

1. Srivastava A, Brewer AK, MauserSBunschoten EP et al. Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1V14.10.1111/j.1365-2516.2012.02909.x
Open DOI Search in Google Scholar Back to article
2. Hilgartner MW, Makipernaa A, DiMichele DM. LongSterm FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261V8.10.1046/j.1365-2516.2003.00771.x
Search in Google Scholar Back to article
3. Valentino LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 2006; 12TSuppl. 5U: 26V31.10.1111/j.1365-2516.2006.01382.x
Open DOI Search in Google Scholar Back to article
4. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate TFEIBA©U reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249V55.10.1111/j.1365-2516.2007.01442.x
Open DOI Search in Google Scholar Back to article
5. Leissinger C, Gringeri A, Antmen B et al. AntiSinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684V92.10.1056/NEJMoa1104435
Search in Google Scholar Back to article
6. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and onSdemand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65S72.10.1111/hae.12246
Search in Google Scholar Back to article
7. Hoots WK, Ebbesen LS, Konkle BA et al, Novoseven TF7HAEMS1505U Investigators. Secondary prophylaxis with recombinant activated factor VII improves healthS related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466V75.10.1111/j.1365-2516.2008.01654.x
Open DOI Search in Google Scholar Back to article
8. Ekert H, Brewin T, Boey W, et al. CostSutility analysis of recombinant factor VIIa TNovoSevenU in six children with longSstanding inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279V85.10.1046/j.1365-2516.2001.00502.x
Search in Google Scholar Back to article
9. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154V62.10.1111/j.1365-2516.2006.01204.x
Open DOI Search in Google Scholar Back to article
10. van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, De KP, van den Berg HM, et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10T5U: 565S71.10.1111/j.1365-2516.2004.01016.x
Search in Google Scholar Back to article
11. Groen WG, van der Net J, Helders PJ, Fischer K. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List TPedHALU. Haemophilia 2010; 16: 281S9.10.1111/j.1365-2516.2009.02136.x
Open DOI Search in Google Scholar Back to article
12. Groen W, Van Der Net J, Lacatusu AM, Serban M, et al. Functional limitations in Romanian children with haemophilia; further testing of psychometric properties of the Paediatric Haemophilia Activities List. Haemophilia 2103; 19: e116S125.10.1111/hae.12090
Search in Google Scholar Back to article

FEIBA prophylaxis in a patient with haemophilia and inhibitors

Abstract

Paradigm

My account